Kutatási jelek – Signal Engine

• Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review) — NSCLC
• Emergence of KRAS mosaicism with multiple variants during treatment with alectinib in ALK‑positive metastatic non‑small cell lung cancer: A case report — NSCLC
• Cetuximab co‑treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non‑small cell lung cancer cells — NSCLC
• Computational‑experimental repurposing reveals synergistic sorafenib/hydroxychloroquine response in KRAS‑mutant breast cancer — Breast cancer
• Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS-mutant Pancreatic and Lung Cancer — Pancreatic cancer
• MXD4 enhances resistance to KRAS G12C‑targeted therapy in lung adenocarcinoma by suppressing ACSL4‑mediated ferroptosis — NSCLC
• KRAS — NSCLC
• New breakthrough in developing more personalized treatments for lung cancer — Head and neck squamous cell carcinoma
• Gut microbiota‑metabolism‑immunity axis: a novel perspective of traditional Chinese medicine in hepatocellular carcinoma treatment — Hepatocellular carcinoma
• Preclinical exploration and current clinical applications of immunotherapeutic strategies for hepatocellular carcinoma — Hepatocellular carcinoma
• Frontiers | Research progress of tertiary lymphoid structure in hepatocellular carcinoma: from prognostic biomarkers to new strategies for immunotherapy — Hepatocellular carcinoma
• Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study — Multiple myeloma
• Linvoseltamab versus real‑world International Myeloma Working Group standard‑of‑care in triple‑class exposed relapsed/refractory multiple myeloma — Multiple myeloma
• Tumour‑intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma — Multiple myeloma
• Redefining light‑chain smoldering multiple myeloma: prevalence and progression risk — Multiple myeloma
• Pharmacokinetics of CAR T cells in multiple myeloma 1 the good, the bad, and the ugly — Prostate cancer
• Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases — Multiple myeloma
• Expert Review of Clinical Pharmacology, 2026, volume 19, issue 5, pages 409-418. — Myelofibrosis
• Frontiers | Precision medicine in myelofibrosis: from molecular profiling to personalized therapy — Myelofibrosis
• Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival. — Myelofibrosis